key: cord-0916222-58qv133h authors: Zouboulis, C.C.; van Laar, J.A.M.; Schirmer, M.; Emmi, G.; Fortune, F.; Gül, A.; Kirino, Y.; Lee, E.‐S.; Sfikakis, P.P.; Shahram, F.; Wallace, G.R. title: Adamantiades‐Behçet's disease (Behçet's disease) and COVID‐19 date: 2021-05-13 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17325 sha: a0bb0265431ab0c06b1ba4cca159d168cb6cb1ef doc_id: 916222 cord_uid: 58qv133h The immunopathogenesis of COVID-19 remains ill-defined. Through hyperstimulation of the immune system, SARS-CoV2 may cause a multi-facetted inflammatory disease and generate immune-mediated organ damage even leading to fatal consequences. However, it is still unclear, if a modified course of COVID-19 occurs in patients with autoimmune and/or autoinflammatory diseases. The immunopathogenesis of COVID-19 remains ill-defined. 1 Through hyperstimulation of the immune system, SARS-CoV2 may cause a multi-facetted inflammatory disease and generate immune-mediated organ damage even leading to fatal consequences. 2 However, it is still unclear, whether a modified course of COVID-19 occurs in patients with autoimmune and/or autoinflammatory diseases. 3, 4 Among them, Adamantiades-Behc ßet's disease (ABD; Behc ßet's disease) is a rare, multisystem, inflammatory disease characterized by variable vessel vasculitis and relapsing-remitting course, exhibiting both autoimmune and autoinflammatory signs. 5 So far, rudimentary data on COVID-19 in ABD patients and no information about the proper management of ABD patients in the pandemic period exist. In a telematic survey of 2789 Spanish patients, 28 had uveitis due to a systemic autoimmune disease. 6 Among them, 12 were ABD patients; with six reporting clinical manifestations compatible with COVID-19. Moreover, among 2135 consecutive COVID-19 patients presented to the Hospital Cl ınic (Barcelona, Spain), four (0.19%) were co-diagnosed with ABD and three were hospitalized. 7 In all four patients, ABD activity during the first COVID-19 symptoms was low. No patient required intensive care unit (ICU) treatment or mechanical ventilation. Further, 51 of 54 ambulatory ABD patients of the Necmettin Erbakan University Hospital (Konya, Turkey) continued their immunological treatment during the pandemic period; none of them developed COVID-19. 8 Lastly, among 10 ABD patients of the Cerrahpasa Medical School (Istanbul, Turkey) with COVID-19, eight were hospitalized (median hospitalization length 7 days, interquartile range 5.5-10). Two patients were admitted to the ICU and a patient, not been on treatment for ABD before getting COVID-19, died. 9 COVID-19 symptoms were mild in the nine patients who survived, and three patients reported exacerbations of their ABD-associated oral ulcers or arthralgia. In a digital conference of the International Society for Behc ßet's disease, which took place on 22 January 2021, ABD experts reported on the association of ABD with COVID-19 in their countries (Table 1) . With exception of the Netherlands, where ABD patients presented a significantly higheralmost twofold -COVID-19 prevalence (11.55%) than the general population (6.31%), the overall prevalence of COVID-19 in ABD patients at 0.61% was significantly lower -4.4-foldthan that in the general population (2.71%, P < 0.00001). Hospitalization due to COVID-19 symptoms was required in 33 of 168 COVID-19+ ABD patients (19.6%) and ICU in two patients (1.19%). Three ABD patients deceased with COVID-19 (1.79%). The participants analysed the available data and the existing literature and based on the current evidence concluded on a list of measurements to be taken from ABD patients and their physicians during the COVID-19 pandemic: • The prevalence of COVID-19 in patients with ABD is apparently lower than that in the general population. This may be due to ABD patients having been especially careful with social shielding. • ABD appears not to be associated with a more severe COVID-19 course, although the number of reported cases is still low to be able to analyse the effects of disease subtypes, activity and medications on COVID-19 outcome. • Treatment of ABD with low-dose prednisolone (<10 mg/day) and/or biologics (esp. TNF-a inhibitors) seems not to increase the risk for COVID-19 or induce a more severe course. • Treatment initiation of ABD with high-dose prednisolone, cyclosporine A, methotrexate or cyclophosphamide should be carefully evaluated at the individual level, given some concern of increasing COVID-19 severity in general population. Patients that are already receiving these drugs should strictly adhere to self-protection and hygiene measurements. • Although the effect of vaccination on ABD (and vice versa) is as yet unknown, anti-SARS-CoV2 vaccination is recommended. It may be advisable not to vaccinate during a significant flare of ABD. Benefits of being vaccinated versus risk of developing severe COVID-19 should be considered at an individual level, but in general possible risks of vaccination do not outweigh the potential dangers of COVID-19. • Treatment with biologics in ABD appears: -To be compatible with SARS-CoV2 vaccination during ABD remission or low disease activity and should not be interrupted. -Not to compromise SARS-CoV2 vaccination. Serological confirmation of successful vaccination by ELISA may be recommended. • National self-protection and hygiene measurements should be adhered to. Self-protection with masks is recommended even after vaccination. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses The SARS-CoV-2 as an instrumental trigger of autoimmunity COVID-19 in autoinflammatory diseases with immunosuppressive treatment Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis Differential clinical presentation of Adamantiades-Behcet's disease in non-endemic and endemic areas: retrospective data from a Middle-European cohort study Impact of novel coronavirus infection in patients with uveitis associated with an autoimmune disease: result of the COVID-19-GEAS patient survey COVID-19 and Behcet's disease: clinical case series Management of patients with Behcet's disease during the COVID-19 pandemic Characteristics and outcomes of Behcet's syndrome patients with Coronavirus Disease 2019: a case series of 10 patients The authors acknowledge the contribution of Prof. Dorian O. Haskard, National Heart and Lung Institute, Imperial College London, Hammersmith Campus, London, UK during the consensus procedure and thank the Associazione Sindrome e Malattia di Behc ßet e Behc ßet-like odv, Dr. Andreas Altenburg and Sophie den Otter for support on data collection. The Depart-